Europe
Recipharm, the contract development and manufacturing organisation, has launched Recipharm Analytical Solutions™, a stand-alone service to support pharmaceutical companies with their Quality Control and analytical requirements.
Endorsement of pivotal development program in recurrent glioblastoma (rGBM) from both EMA and FDA
Data support potential of ADCT-402 to become an important treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, will announce a trading update for the nine-months ended 30 September 2019 on Tuesday, 5 November 2019.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
The versatile drug currently treats locally advanced or metastatic urothelial carcinoma, metastatic non-small cell lung cancer, metastatic triple-negative breast cancer, and extensive-stage small cell lung cancer.
It was the first randomized, controlled trial comparing Toujeo to Gla-100 in this patient population.
Recipharm, the contract development and manufacturing organisation, and CTC Clinical Trial Consultants have strengthened their partnership with the divestment of Recipharm’s GLP bioanalysis business to the Center for Translational Research AB group.
BillionToOne and Eluthia have announced the launch of the first and only non-invasive prenatal test, allowing to screen for the autosomal-recessive conditions cystic fibrosis, spinal muscular atrophy, sickle cell disease and other hemoglobinopathies.
An international team of researchers have put forward a position statement, published in Science, whichlays out a new healthcare framework to help aging populations stay healthier for longer.
PRESS RELEASES